» Articles » PMID: 33383892

Raman Spectroscopy Discloses Altered Molecular Profile in Thyroid Adenomas

Abstract

Follicular patterned nodules are sometimes complex to be classified due to ambiguous nuclear features and/or questionable capsular or vascular invasion. In this setting, there is a poor inter-observer concordance even among expert pathologists. Raman spectroscopy was recently used to separate benign and malignant thyroid nodules based on their molecular fingerprint; anyway, some histologically proved follicular adenomas were clustered as having a characteristic profile of malignant lesions. In this study, we analyzed five follicular thyroid adenomas with a malignant spectroscopic profile compared to five follicular adenomas with a benign Raman spectrum in order to assess possible molecular differences between the two groups. Morphological, immunohistochemical, and molecular analyses evidenced expression of malignancy-associated proteins in four out of five malignant clustered adenomas. The remaining malignant clustered adenoma showed a mutation previously associated with autonomously functioning follicular carcinomas. In conclusion, thyroid follicular adenomas are a group of morphologically benign neoplasms that may have altered the mutational or expression profile; cases of adenomas with altered immunophenotype are recognized as showing a profile associated with malignancy by Raman spectroscopy. This correlation warrants a more extensive evaluation and suggests a potential predictive value of spectroscopic assessment in recognizing characteristics associated with tumor progression in follicular thyroid neoplasms.

Citing Articles

An eXplainable Artificial Intelligence analysis of Raman spectra for thyroid cancer diagnosis.

Bellantuono L, Tommasi R, Pantaleo E, Verri M, Amoroso N, Crucitti P Sci Rep. 2023; 13(1):16590.

PMID: 37789191 PMC: 10547772. DOI: 10.1038/s41598-023-43856-7.


Unraveling the Effects of Carotenoids Accumulation in Human Papillary Thyroid Carcinoma.

Di Masi A, Sessa R, Cerrato Y, Pastore G, Guantario B, Ambra R Antioxidants (Basel). 2022; 11(8).

PMID: 36009182 PMC: 9405418. DOI: 10.3390/antiox11081463.


Update on International Medical Taxonomies of Biomarkers and Their Applications in Management of Thyroid Cancers.

Trovato M Diagnostics (Basel). 2022; 12(3).

PMID: 35328215 PMC: 8946984. DOI: 10.3390/diagnostics12030662.


Recent Advances in the Label-Free Characterization of Exosomes for Cancer Liquid Biopsy: From Scattering and Spectroscopy to Nanoindentation and Nanodevices.

Di Santo R, Romano S, Mazzini A, Jovanovic S, Nocca G, Campi G Nanomaterials (Basel). 2021; 11(6).

PMID: 34199576 PMC: 8230295. DOI: 10.3390/nano11061476.

References
1.
Pozdeyev N, Gay L, Sokol E, Hartmaier R, Deaver K, Davis S . Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018; 24(13):3059-3068. PMC: 6030480. DOI: 10.1158/1078-0432.CCR-18-0373. View

2.
Ye L, Zhou X, Huang F, Wang W, Qi Y, Xu H . The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing. Nat Commun. 2017; 8:15533. PMC: 5465355. DOI: 10.1038/ncomms15533. View

3.
Fuhrer D, Tannapfel A, Sabri O, Lamesch P, Paschke R . Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocr Relat Cancer. 2004; 10(4):591-600. DOI: 10.1677/erc.0.0100591. View

4.
Kallaway C, Almond L, Barr H, Wood J, Hutchings J, Kendall C . Advances in the clinical application of Raman spectroscopy for cancer diagnostics. Photodiagnosis Photodyn Ther. 2013; 10(3):207-19. DOI: 10.1016/j.pdpdt.2013.01.008. View

5.
Nardi F, Basolo F, Crescenzi A, Fadda G, Frasoldati A, Orlandi F . Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014; 37(6):593-9. DOI: 10.1007/s40618-014-0062-0. View